Increasing Medical Marijuana and Cannabidiol Research

This EO directs the expedited rescheduling of marijuana from Schedule I to Schedule III, acknowledging its accepted medical use and reduced abuse potential. It further calls for a regulatory framework and improved research on both medical marijuana and hemp-derived CBD products, including clear guidance on THC limits and accurate product labeling. The order aims to close gaps in medical knowledge so patients and providers may access safe, effective, and well-informed treatment options.

• DOJ
• HHS
• NIH

Immediate.

None.

No known legal challenges.